Besides, Hoque and colleagues described the combined methylation analysis of CDKN2A, MGMT and GSTP1 using urine, enabling the differentiation between BC patients and control subjects, achieving 69% sensitivity and 100% specificity [112]. Here, CDKN2A is linked to breast cancer.